Institution of an antimicrobial stewardship program (ASP) is a key method of combating antimicrobial resistance. ASPs have been increasingly reported to be effective and safe among children [1, 2] . Antibiotic stewardship in the pediatric intensive care unit (PICU) poses a special dilemma in that the majority of patients are critically ill and physicians must balance concerns about antimicrobial resistance with the use of broad-spectrum antimicrobial agents. Inappropriate initial antimicrobial therapy for septic shock can result in one-fifth survival rate [3] . In contrast, unnecessarily prolonged use of broad-spectrum antimicrobials can cause antimicrobial resistance and adverse events that affect patient outcomes [4] . Nonetheless, ASP implementation is recommended for all intensive care units [5] . ASP interventions in adults have been found to reduce the incidence of infections by multidrug-resistant organisms [6] and prevent the acquisition of multidrug-resistant Gram-negative bacteria [7] .
Few studies have focused on the PICU population. One study implemented guidelines using education, a retrospective review, feedback, and a prospective audit [8] . In adults, regular collaboration between infectious disease and intensive care unit physicians led to successful outcomes [9] . To the best of our knowledge, no studies on the effects of an ASP combined with infectious disease consultations in a PICU have been reported. Our consultations were unique in that infectious disease physicians were routinely involved in patient care in the PICU for any aspect of infectious disease by participating in the daily PICU rounds regardless of the complexity, severity, and/or rarity of the disease involved. The aim of this study was to evaluate the effects of ASP interventions in our PICU combined with infectious disease consultations through active communication between pediatric infectious disease and PICU physicians.
MATERIALS AND METHODS

Study Design
The study was conducted at the PICU of Tokyo Metropolitan Children's Medical Center in Japan, which has 22 beds. Our hospital opened in March 2010, and the PICU began operating partially in April 2010 and fully in December 2010. We conducted a preintervention/postintervention analysis of antipseudomonal antibiotic use after the introduction of an ASP between April 2010 and December 2015. The number of extracorporeal membrane oxygenation (ECMO) runs per 1000 patient-days was used as an indicator of illness severity. The number of pediatric infectious disease and PICU physicians and the number of consultations performed by the pediatric infectious disease service per 1000 patient-days were counted. The primary outcome was the consumption of antipseudomonal agents, as measured by days of therapy per 1000 patient-days (DOT/1000 patient-days). The drugs included meropenem, piperacillin-tazobactam, ciprofloxacin, amikacin, levofloxacin, piperacillin, ceftazidime, cefepime, and gentamicin. The secondary outcomes were mean length of PICU stay, number of infection-related deaths per 1000 patient-days, and rate of PICU readmissions within 48 hours per 1000 patient-days. Infection-related death was defined as death related to microbiologically confirmed infection or infection clinically diagnosed by a pediatric infectious disease physician. The consumption of nonantipseudomonal agents was also measured in DOT/1000 patient-days. The drugs included penicillin G, ampicillin, ampicillin-sulbactam, cefazolin, cefotiam, cefmetazole, cefotaxime, and ceftriaxone. This study was approved by the institutional review board at Tokyo Metropolitan Children's Medical Center (approval H28b-92).
Infectious Disease Consultations and ASP Interventions
Pediatric infectious disease physicians attended the PICU morning rounds every day to discuss infectious disease management as part of their consultations. All patients on antimicrobials were discussed. On-call pediatric infectious disease physicians responded to requests for consultation any time of the day. The consultations included (1) the antimicrobial indication for patients suspected of having an infection and advice on microbiological investigations, (2) selection, dosing, and duration of antimicrobials, and (3) interpretation of culture results and advice on discontinuation, deescalation, or escalation of antimicrobials. The preintervention period between April 2010 and September 2011 consisted only of consultations. An ASP team was formed with pediatric infectious disease physicians, pharmacists, microbiologists, and clerks in October 2011. The postintervention period for the ASP was from October 2011 to December 2015. ASP interventions included preauthorization with an infectious diseases physician for prescriptions for meropenem, piperacillin-tazobactam, amikacin, ciprofloxacin, and levofloxacin, restrictive susceptibility reporting on meropenem, amikacin, and levofloxacin, therapeutic drug monitoring performed by a pharmacist, and molecular microbiological testing for viruses and bacteria that prove difficult to isolate by culture. Piperacillintazobactam was on the list of restricted antipseudomonal agents, because other narrower-spectrum agents remained susceptible to Pseudomonas aeruginosa.
Statistical Analysis
An interrupted time-series (ITS) analysis was used to evaluate changes in the DOT/1000 patient-days for total antipseudomonal and nonantipseudomonal agents per month between the preintervention and postintervention periods. The changes in number of ECMO runs per 1000 patient-days, infection-related deaths per 1000 patient-days, and rate of PICU readmissions within 48 hours per 1000 patient-days during the study period were compared annually using the χ 2 test for trend. The mean length of stay in the PICU was compared annually using 1-way ANOVA with Bonferroni correction. Statistics 23 (IBM SPSS, Chicago, Illinois) was used for the data analyses. A 2-tailed P value of < .05 was considered statistically significant.
RESULTS
Overall, 27 622 patient-days were analyzed during the study period. ITS analysis revealed that the ASP interventions provoked a significant reduction in the level and trend of DOT/1000 patient-days for total antipseudomonal agents ( Figure 1 ; Supplementary Table 1 ). In contrast, ITS analysis showed a significant change in trend but not in level of DOT/1000 patient-days for nonantipseudomonal agents with the ASP interventions (Supplementary Figure 1; Supplementary Table 1 ). The DOT/1000 patient-days changed from 288 in 2010 to 219 in 2015 (−24%) for total antipseudomonal agents. The mean lengths of PICU stay in the preintervention and postintervention periods were 5.4 days (95% CI, 5.0-5.7 days) and 5.4 days (95% CI, 5.1-5.6 days), respectively, which indicates no significant change (P = .563). The mean numbers of infection-related deaths per 1000 patient-days in the preintervention and postintervention periods were 1.1 (95% CI, 0.2-2.1) and 1.6 (95% CI, 1.1-2.1), respectively, also indicating no significant difference (P = .556). Furthermore, the mean numbers of PICU readmissions within 48 hours per 1000 patient-days in the preintervention and postintervention periods were 1.6 (95% CI, 0.4-2.7) and 0.9 (95% CI, 0.3-1.4), respectively, which indicates no significant difference during the study period (P = .497).
DISCUSSION
Our ASP interventions significantly reduced the use of total antipseudomonal agents (Figure 1 ). Immediate and significant reductions in antimicrobial use can be expected by formulary restrictions and preauthorization requirements [10] . Because the numbers of pediatric infectious disease physicians increased steadily, an approximately 3-fold increase in the number of consultations was seen. Regarding nonantipseudomonal agents that might reflect the effect of consultations, although a decreasing trend was observed in the preintervention period, the trend remained low and steady in the postintervention period (Supplementary Figure 1, Supplementary Table 1 ). We occasionally faced hesitation by the PICU physicians to discontinue or deescalate antimicrobial agents because of disease severity in a patient. However, we continued our discussion to reach an agreement with the goal of improving our patient care. Our additional availability of in-house molecular testing of microorganisms might have helped in decisions to switch from empirical to specific treatment.
Preauthorization and selective susceptibility reporting might have caused a shift from the use of restricted to nonrestricted agents with increased resistance [10] [11] [12] . In this study, the total consumption of antipseudomonal agents decreased without susceptibilities worsening.
The benefits of implementing an ASP include improved patient outcomes [11] and ensuring that the safety profile remains important. A previous PICU study reduced the use of targeted broad-spectrum antimicrobial agents without changing the length of stay or mortality rate [8] . In this study, the total use of antipseudomonal agents was reduced successfully without changing the length of stay, the infection-related mortality rate, or the rate of readmissions to the PICU within 48 hours.
There were several limitations to this study. First, we did not evaluate the severity of the patients' condition by means of objective scoring except for using the number of ECMO runs. Second, it was difficult to evaluate the effects of the ASP and consultations individually. Detailed contents of the consultations might have been helpful for that purpose, but they were unavailable in this study. Third, the secondary outcomes of this study might not have been the most sensitive indicators of antibiotic treatment failure. Fourth, the preintervention period was less than 1 year after full operation of this new PICU, given that antibiotic use might have depended on the seasonality of pediatric illness. Fifth, the effect of molecular microbiological testing was difficult to evaluate. However, it was helpful to discontinue antimicrobials when a viral pathogen was identified. Sixth, the susceptibility of Pseudomonas aeruginosa in the PICU was not evaluated, because there was an insufficient number of isolates for analysis. Last, this study was conducted at only 1 hospital.
In conclusion, our ASP interventions combined with infectious disease consultations reduced the use of broad-spectrum antimicrobials with no change in length of stay, infection-related mortality rate, or rate of PICU readmissions within 48 hours.
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